474 related articles for article (PubMed ID: 16099292)
1. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.
Rabe KF; Bateman ED; O'Donnell D; Witte S; Bredenbröker D; Bethke TD
Lancet; 2005 Aug 13-19; 366(9485):563-71. PubMed ID: 16099292
[TBL] [Abstract][Full Text] [Related]
2. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
[TBL] [Abstract][Full Text] [Related]
3. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
[TBL] [Abstract][Full Text] [Related]
4. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Calverley PM; Rabe KF; Goehring UM; Kristiansen S; Fabbri LM; Martinez FJ;
Lancet; 2009 Aug; 374(9691):685-94. PubMed ID: 19716960
[TBL] [Abstract][Full Text] [Related]
5. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
Fabbri LM; Calverley PM; Izquierdo-Alonso JL; Bundschuh DS; Brose M; Martinez FJ; Rabe KF;
Lancet; 2009 Aug; 374(9691):695-703. PubMed ID: 19716961
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
Janjua S; Fortescue R; Poole P
Cochrane Database Syst Rev; 2020 May; 5(5):CD002309. PubMed ID: 32356609
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
Rabe KF; Watz H; Baraldo S; Pedersen F; Biondini D; Bagul N; Hanauer G; Göhring UM; Purkayastha D; Román J; Alagappan VKT; Saetta M
Lancet Respir Med; 2018 Nov; 6(11):827-836. PubMed ID: 30224319
[TBL] [Abstract][Full Text] [Related]
8. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma.
Bousquet J; Aubier M; Sastre J; Izquierdo JL; Adler LM; Hofbauer P; Rost KD; Harnest U; Kroemer B; Albrecht A; Bredenbröker D
Allergy; 2006 Jan; 61(1):72-8. PubMed ID: 16364159
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Leung B; Poole P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
[TBL] [Abstract][Full Text] [Related]
10. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
Rutten-van Mölken MP; van Nooten FE; Lindemann M; Caeser M; Calverley PM
Pharmacoeconomics; 2007; 25(8):695-711. PubMed ID: 17640111
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Leung B; Poole P
Cochrane Database Syst Rev; 2013 Nov; (11):CD002309. PubMed ID: 24190161
[TBL] [Abstract][Full Text] [Related]
12. Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.
Porpodis K; Domvri K; Zarogoulidis P; Petridis D; Tsirgogianni K; Papaioannou A; Hatzizisi O; Kioumis I; Liaka A; Kikidaki V; Lampaki S; Organtzis J; Zarogoulidis K
Int J Chron Obstruct Pulmon Dis; 2015; 10():1123-8. PubMed ID: 26109853
[TBL] [Abstract][Full Text] [Related]
13. Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial.
Lee SD; Hui DS; Mahayiddin AA; Roa CC; Kwa KH; Goehring UM; Bredenbröker D; Kuo HP
Respirology; 2011 Nov; 16(8):1249-57. PubMed ID: 21848706
[TBL] [Abstract][Full Text] [Related]
14. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
[TBL] [Abstract][Full Text] [Related]
15. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
16. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD.
Hanania NA; Calverley PM; Dransfield MT; Karpel JP; Brose M; Zhu H; Goehring UM; Rowe P
Respir Med; 2014 Feb; 108(2):366-75. PubMed ID: 24120253
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.
Yan JH; Gu WJ; Pan L
Pulm Pharmacol Ther; 2014 Feb; 27(1):83-9. PubMed ID: 23624309
[TBL] [Abstract][Full Text] [Related]
18. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Pinner NA; Hamilton LA; Hughes A
Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of roflumilast in the treatment of asthma.
Bateman ED; Izquierdo JL; Harnest U; Hofbauer P; Magyar P; Schmid-Wirlitsch C; Leichtl S; Bredenbröker D
Ann Allergy Asthma Immunol; 2006 May; 96(5):679-86. PubMed ID: 16729780
[TBL] [Abstract][Full Text] [Related]
20. Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history.
Bateman ED; Rabe KF; Calverley PM; Goehring UM; Brose M; Bredenbröker D; Fabbri LM
Eur Respir J; 2011 Sep; 38(3):553-60. PubMed ID: 21737553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
